TITLE:
Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

CONDITION:
Ovarian Neoplasms

INTERVENTION:
OSI-211 (Liposomal Lurtotecan)

SUMMARY:

      The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in
      patients with relapsed epithelial ovarian cancer.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Confirmed relapsed ovarian cancer.

          -  Measurable disease greater than or equal to 20 mm (or greater than or equal to 10 mm
             on spiral CT scan).

          -  One or two prior regimens of chemotherapy. At least one regimen must have contained
             cisplatin or carboplatin.

          -  At least three weeks since prior chemotherapy and recovery from any related
             toxicities.

          -  At least four weeks since prior radiotherapy and recovery from any related
             toxicities.
      
